Dova Pharmaceuticals, which is commercializing an acquired drug candidate for low blood platelets, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The Durham, NC-based company was formed in 2016 and plans to list on the Nasdaq under the symbol DOVA. Dova Pharmaceuticals filed confidentially on April 21, 2017. J.P. Morgan, Jefferies and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
